1. HBW Insight
  2. >>Leadership

Makary Suggests Combining All FDA Adverse Event Reporting Systems

 
• By Sarah Karlin-Smith

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

Martin Makary Senate Confirmation Hearing
FDA Commissioner nominee Martin Makary faced questions about a cancelled vaccines advisory committee meeting at his confirmation hearing. (Screenshot of Senate Broadcast)
Key Takeaways
  • FDA Commissioner Martin Makary suggested combining all of FDA's adverse event reporting systems, currently divided by product area into separate systems, into one.

US Food and Drug Administration Commissioner Martin Makary is considering combining all of the agency’s adverse event reporting systems into...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Biotech Investor, One-Time US FDA Commissioner Candidate Returns To HHS As RFK Jr.’s Top Deputy

 
• By Malcolm Spicer

Jim O’Neill recently was CEO of age-related diseases group SENS Research Foundation. After serving in HHS from 2002 to 2008, he became a managing director of Clarium Capital global investment fund and was Thiel Foundation CEO, funding nonprofits that promote technology.

More from HBW Insight

Consumers More Often Choosing Private Label First

 
• By Malcolm Spicer

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 
• By Malcolm Spicer

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 
• By Malcolm Spicer

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.